A recently discovered coronavirus, SARS-CoV-2, caused a global respiratory disease pandemic called COVID-19. Many studies have shown the excessive activation of the innate immune response that leads to the adverse outcomes of COVID-19, and anti-inflammatory drugs are very useful in the treatment and management of this infection. The activities of Colchicine, one of the anti-inflammatory drugs, target several pathways related to excessive inflammation of COVID-19. This study aimed to evaluate the efficacy of Colchicine in the treatment of COVID-19 using a meta-analysis approach. Scopus, Pubmed, Google scholars, Web of Science, and Science direct were used to search all the randomized controlled trials, case-control, and cross-sectional studies that have evaluated the efficacy of Colchicine as a treatment for COVID-19 (up to 28 May 2021). The overall effect of Colchicine versus the control group was determined using a random-effects model meta-analysis where we compared changes (i.e. mean differences—Colchicine group vs Control group) between the two conditions in test scores indicative of hospitalization time (day) and mortality rate. The results illustrated Colchicine therapy is associated with a decreased mortality rate in COVID-19 patients and associated with a decrease in hospitalization time (day) in COVID-19 patients. Present preliminary data shows that Colchicine has a beneficial effect on coronavirus disease care in 2019. Therefore, Colchicine can be a good suggestion in the management of COVID-19.

最近发现的一种冠状病毒 SARS-CoV-2 引起了名为 COVID-19 的全球呼吸道疾病大流行。许多研究表明，先天免疫反应的过度激活会导致 COVID-19 的不良后果，而抗炎药物在治疗和管理这种感染方面非常有用。秋水仙碱是一种抗炎药，其活性针对与 COVID-19 过度炎症相关的多种途径。本研究旨在利用荟萃分析方法评估秋水仙碱治疗 COVID-19 的疗效。Scopus、Pubmed、Google 学者、Web of Science 和 Science direct 被用来检索所有评估秋水仙碱治疗 COVID-19 疗效的随机对照试验、病例对照和横断面研究（最多2021 年 5 月 28 日）。秋水仙碱与对照组的总体效果是使用随机效应模型荟萃分析确定的，其中我们比较了两种情况之间指示住院时间（天）和死亡率。结果表明，秋水仙碱治疗可降低 COVID-19 患者的死亡率，并缩短 COVID-19 患者的住院时间（天）。目前的初步数据表明，秋水仙碱对 2019 年冠状病毒疾病的护理具有有益作用。因此，秋水仙碱可以作为治疗 COVID-19 的一个很好的建议。